NICE Nod For Selincro May Give Lundbeck Much Needed Revenue Boost
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE's positive recommendation for Lundbeck's Selincro for alcohol dependence should give the Danish biotech a revenue boost and help offset expiry of its Lexapro/Cipralex patent.